Archives of Medical Research
Volume 40, Issue 7 , Pages 600-604 , October 2009

Influence of Genetic Polymorphism in Matrix Metalloproteinase-3 on Extent of Coronary Atherosclerosis and Risk of Coronary Artery Stenosis

  • Morteza Seifi

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Morteza Seifi, Biochemistry Department, Faculty of Medicine, Iran University of Medical Sciences, P.O. Box 1449614525, Hemmat Highway, Tehran, Iran; Phone and Fax: (98) 21-88058742, ext. 3116
    • ,
  • Soudabeh Fallah
    • ,
  • Mohsen Firoozrai

Received 26 May 2009 ,Accepted 7 August 2009.

References 

  1. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci. 1999;878:212–227
  2. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes. Neuroimmunomodulation. 1996;3:69–75
  3. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21492–21494
  4. Verstappen J, Von den Hoff JW. Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral diseases. J Dent Res. 2006;85:1074–1084
  5. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262
  6. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation. 2001;104:1878–1880
  7. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623–629
  8. Gerad-Mizon F, de Groote P, Lamblin N, et al. Prognostic impact of matrix metalloproteinase gene polymorphism in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J. 2004;25:688–693
  9. Fang S, Jin X, Wang R, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis. 2005;26:481–486
  10. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 1991;88:8154–8158
  11. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145–2154
  12. Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–13060
  13. Beyzade S, Zhang S, Wong YK, et al. Influences of matrixmetalloproteinase-3 gene variation on extent of coronary atherosclerosisand risk of myocardial infarction. J Am Coll Cardiol. 2003;41:2130–2137
  14. Liu PY, Li YH, Chan SH, et al. Genotype–phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol. 2006;98:1012–1017
  15. Zhou X, Huang J, Chen J, et al. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study Thromb Haemost. 2004;92:867–873
  16. Kim JS, Park HY, Kwon JH, et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J. 2002;43:473–481
  17. Lamblin N, Bauters C, Hermant X, et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9, and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002;40:43–48
  18. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:27179
  19. Nojiri T, Morita H, Imai Y, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol. 2003;92:181–186
  20. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost. 2003;90:132–139
  21. Ye S, Watts GF, Mandalia S, et al. Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215
  22. Humphries SE, Luong LA, Talmud PJ, et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis. 1998;139:49–56
  23. de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol. 1999;83:852–856
  24. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003;42:1429–1437
  25. Schwarz A, Haberbosch W, Tillmanns H, et al. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers. 2002;18:121–128
  26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
  27. Hoppmann P, Koch W, Schomig A, et al. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:335–341
  28. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J. 2003;24:1668–1671
  29. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  30. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  31. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996;94:2013–2020
  32. Silence J, Lupu F, Collen D, et al. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440–1445
  33. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189–218

PII: S0188-4409(09)00150-7

doi: 10.1016/j.arcmed.2009.08.008

Archives of Medical Research
Volume 40, Issue 7 , Pages 600-604 , October 2009

Article Tools